HUM Stock Forecast 2025-2026
Distance to HUM Price Targets
HUM Price Momentum
10 Quality Stocks Worth Considering Now
Researching Humana (HUM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on HUM and similar high-potential opportunities.
Latest HUM Stock Price Targets & Analyst Predictions
Based on our analysis of 37 Wall Street analysts, HUM has a neutral consensus with a median price target of $286.50 (ranging from $241.00 to $402.23). The overall analyst rating is Buy (6.9/10). Currently trading at $270.48, the median forecast implies a 5.9% upside. This outlook is supported by 7 Buy, 19 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HUM Analyst Ratings
HUM Price Target Range
Latest HUM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HUM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 18, 2025 | JP Morgan | Lisa Gill | Neutral | Maintains | $256.00 |
| Feb 13, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $270.00 |
| Feb 12, 2025 | Cantor Fitzgerald | Sarah James | Neutral | Reiterates | $290.00 |
| Feb 12, 2025 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $283.00 |
| Feb 12, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $285.00 |
| Jan 22, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $255.00 |
| Jan 15, 2025 | Piper Sandler | Jessica Tassan | Neutral | Maintains | $288.00 |
| Jan 6, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $290.00 |
| Dec 17, 2024 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $301.00 |
| Nov 6, 2024 | B of A Securities | Kevin Fischbeck | Neutral | Upgrade | $308.00 |
| Nov 4, 2024 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $290.00 |
| Nov 4, 2024 | TD Cowen | Gary Taylor | Hold | Maintains | $268.00 |
| Oct 31, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $253.00 |
| Oct 11, 2024 | Keybanc | Matthew Gillmor | Sector Weight | Initiates | $0.00 |
| Oct 11, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $260.00 |
| Oct 10, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $250.00 |
| Oct 9, 2024 | Stephens & Co. | Scott Fidel | Equal-Weight | Reiterates | $250.00 |
| Oct 8, 2024 | Bernstein | Lance Wilkes | Outperform | Upgrade | $308.00 |
| Oct 8, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $265.00 |
| Oct 7, 2024 | TD Cowen | Gary Taylor | Hold | Downgrade | $261.00 |
Humana Inc. (HUM) Competitors
The following stocks are similar to Humana based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Humana Inc. (HUM) Financial Data
Humana Inc. has a market capitalization of $32.65B with a P/E ratio of 27.1x. The company generates $117.76B in trailing twelve-month revenue with a 1.0% profit margin.
Revenue growth is +10.4% quarter-over-quarter, while maintaining an operating margin of -0.7% and return on equity of +7.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Humana Inc. (HUM) Business Model
About Humana Inc.
Provides comprehensive health insurance products and services.
Humana operates primarily in the healthcare insurance sector, generating revenue through a variety of health insurance products, including Medicare Advantage plans and individual/group medical plans. The company serves both individual consumers and large organizations, focusing on tailored healthcare coverage and preventive care. Its business model is bolstered by participation in government-sponsored healthcare programs and partnerships that enhance integrated care.
Based in Louisville, Kentucky, Humana is a significant player in the U.S. healthcare system, emphasizing wellness and striving to improve health outcomes. The company is actively enhancing its digital solutions to stay competitive in the evolving healthcare landscape.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
65,680
CEO
Mr. James A. Rechtin M.B.A.
Country
United States
IPO Year
1981
Website
www.humana.comHumana Inc. (HUM) Latest News & Analysis
HUM's easy patient accessibility may provide a competitive advantage over other senior-focused healthcare providers.
HUM's competitive edge in accessibility may lead to increased patient enrollment, potentially driving revenue growth and improving market position in senior healthcare.
CenterWell is launching personalized health care services for seniors at the Walmart in Gladstone, Missouri, enhancing healthcare accessibility for the local community.
CenterWell's partnership with Walmart enhances access to healthcare for seniors, potentially increasing foot traffic and sales, and improving overall market positioning in the growing healthcare sector.
A new specialty care model has been launched, initially in Palm Beach County, by companies based in Louisville, Kentucky, and Stamford, Connecticut.
The introduction of a specialty care model in Palm Beach County could signal new growth opportunities for healthcare providers and influence regional market dynamics, impacting stock valuations.
HUM's CenterWell and Conviva have partnered with Icon Health to enhance musculoskeletal care access for seniors.
The partnership enhances care access for seniors, potentially increasing patient volume and revenue for HUM, positively impacting its stock performance and growth outlook.
AM Best has rated Humana Inc.'s $750M and $500M senior unsecured notes as "bbb" with a stable outlook. Humana's Long-Term Issuer Credit Rating remains "bbb".
Humana's stable credit ratings and new bond issuances indicate financial stability, impacting borrowing costs and investor confidence in the company's long-term performance.
Humana Inc. completed a public offering of $1.25 billion in senior notes, including $750 million at 5.550% due 2035 and $500 million at 6.000% due 2055.
Humana's $1.25 billion senior notes issuance indicates strong capital generation, impacting liquidity and funding for growth, which can influence stock performance and investor sentiment.
Frequently Asked Questions About HUM Stock
What is Humana Inc.'s (HUM) stock forecast for 2025?
Based on our analysis of 37 Wall Street analysts, Humana Inc. (HUM) has a median price target of $286.50. The highest price target is $402.23 and the lowest is $241.00.
Is HUM stock a good investment in 2025?
According to current analyst ratings, HUM has 7 Buy ratings, 19 Hold ratings, and 0 Sell ratings. The stock is currently trading at $270.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HUM stock?
Wall Street analysts predict HUM stock could reach $286.50 in the next 12 months. This represents a 5.9% increase from the current price of $270.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Humana Inc.'s business model?
Humana operates primarily in the healthcare insurance sector, generating revenue through a variety of health insurance products, including Medicare Advantage plans and individual/group medical plans. The company serves both individual consumers and large organizations, focusing on tailored healthcare coverage and preventive care. Its business model is bolstered by participation in government-sponsored healthcare programs and partnerships that enhance integrated care.
What is the highest forecasted price for HUM Humana Inc.?
The highest price target for HUM is $402.23 from at , which represents a 48.7% increase from the current price of $270.48.
What is the lowest forecasted price for HUM Humana Inc.?
The lowest price target for HUM is $241.00 from at , which represents a -10.9% decrease from the current price of $270.48.
What is the overall HUM consensus from analysts for Humana Inc.?
The overall analyst consensus for HUM is neutral. Out of 37 Wall Street analysts, 7 rate it as Buy, 19 as Hold, and 0 as Sell, with a median price target of $286.50.
How accurate are HUM stock price projections?
Stock price projections, including those for Humana Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
